LIN vs RNXT · P/E 34, rev $33.99B vs rev $266.0K
Linde plc Ordinary Shares (LIN) versus RenovoRx Inc (RNXT) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
RenovoRx Inc (RNXT) is a biotechnology company listed on US.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported RNXT revenue for 2025-09-30 was $266.0K. Net income was -$2.9M. Revenue was down 37.0% from 2025-06-30 to 2025-09-30. RNXT currently screens at market cap $47.0M.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. RNXT currently screens at market cap $47.0M.
Not investment advice. Open the LIN and RNXT stock pages for the full models.
Not investment advice.